We describe 2 patients with Parkinson's disease who developed hepatotoxicity associated with the use of entacapone, a novel, mainly peripheral acting inhibitor of catechol-D-methyltransferase. Hepatotoxicity resolved rapidly with discontinuation of the drug. Analysis of causality in a further case initially linked to entacapone exposure was confounded by conflicting serial adverse reaction reports.
No takes yet. Share an insight, caveat, or question.
Fisher et al. (2002) studied this question.
Synapse has enriched one closely related paper. Consider it for comparative context: